RxDoctor Payments Data

Intisab Sultan, MD

Internal Medicine · Selma, CANPI 1548362296

Payments from drug & device makers

$2,437in general payments, 2019–2025

Across 145 payments — averaging $16.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$531
  • Amgen$300
  • Amarin Pharma, Inc.$268
  • Novo Nordisk$191
  • Lilly USA, LLC$169
  • AbbVie$141
  • plus $837 from 16 others

What the payments were for

  • Food & beverage$2,41799%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,437 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$316,256
Medicare patients
222
Services billed
6,255

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin163$178,482
OzempicSemaglutide121$169,796
XareltoRivaroxaban95$99,809
FarxigaDapagliflozin Propanediol98$92,889
EliquisApixaban71$55,408
TrulicityDulaglutide40$50,174
EntrestoSacubitril/Valsartan34$39,766
LinzessLinaclotide27$31,639
JanuviaSitagliptin Phosphate28$31,054
MyrbetriqMirabegron26$22,234
VascepaIcosapent Ethyl37$19,157
RybelsusSemaglutide11$16,656
NuedextaDextromethorphan Hbr/Quinidine11$16,224
TradjentaLinagliptin16$15,918
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog23$14,664

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$89$194,400179 claims
Novo NordiskOzempic, Rybelsus$191$186,452132 claims
Johnson & JohnsonXarelto$115$99,80995 claims
AstraZenecaFarxiga$531$92,88998 claims
PfizerEliquis$77$55,40871 claims
Lilly USA, LLCTrulicity$169$50,17440 claims
NovartisEntresto$107$39,76634 claims
AbbVieLinzess, Namzaric$141$37,63738 claims
MerckJanuvia$33$31,05428 claims
GSKTrelegy Ellipta, Breo Ellipta$98$27,41752 claims
Avanir Pharmaceuticals, Inc.Nuedexta$27$16,22411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Selma

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →